Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis

NCT00423163 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00423163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00423163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized Controlled Trial of Voriconazole (VFEND®) Plus Micafungin (MYCAMINE™) Versus Voriconazole Plus Placebo in the Treatment of Patients With Proven or Probable Invasive Aspergillosis
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Withdrawn
Start date
February 28, 2007
Completion date
Not reported
Enrollment
0 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

aspergillosis/blood, aspergillosis/invasive